"Mr. Collins, we need to clarify a core concept," Huang Jiacai began, his voice clear and determined, "Based on our agreent with the Sanbo Research Institute and the inherent characteristics of system regulation theory, we do not sell a single ’drug’ or ’therapy license.’ What we offer is a ’system dicine solution.’"
"A mandatory, tiered training and certification system. Any partner must start with certification training from the core team of doctors to ensure understanding of the essence, rather than chanical operation."
The Chief Legal Counsel added, "Therefore, our cooperation contract is closer to a long-term, deeply binding technical service and co-developnt agreent. It includes strict implentation standards, data feedback obligations, continuous technical support clauses, and a tiered revenue-sharing model based on efficacy and contribution. A simple upfront paynt plus sales sharing model does not apply here."
mbers of the Collins team exchanged glances. This was far more complex and in-depth than anticipated. This was no longer about purchasing a product, but about connecting to an ecosystem and accepting a whole new set of rules.
"Training system? Data feedback?" A technical commissioner from Novartis couldn’t help asking, "This involves the ownership of core dical data and patient privacy..."
"This is a repeatedly raised issue, and during the process of popularizing K Therapy, we have encountered such concerns, so please rest assured. All data will undergo strict anonymization and encryption before entering our platform, complying with the strictest regulations worldwide. If there is still hesitation on this point, then there is no basis for cooperation," Ruixing’s Chief Science Officer Chen Zhi took over.
"Data ownership remains with the dical institutions and patients, but the usage rights of processed group data belong to the platform for algorithm optimization. This is a compliance frawork designed by legal experts from multiple countries. As for training," he paused, "misunderstanding the system dynamics and misusing the regulation plan poses a far higher risk than traditional targeted drugs. Training is not an obstacle; it is a safeguard, ensuring patient safety and the long-term success of the cooperation project."
Collins listened silently, his fingers unconsciously tapping lightly on the desktop. He had done his howork before coming, knowing the style of Ruixing and Huang Jiacai—precise, assertive, far-sighted, adept at constructing rules rather than just following them. But experiencing it firsthand, he still felt an unprecedented pressure.
"Then, exclusivity?" Collins returned to the original question.
Huang Jiacai smiled slightly, his smile filled with undisputed confidence, "In this erging field of system dicine, premature and excessive exclusivity is not conducive to the healthy developnt of the entire ecosystem and may hinder technological progress. We prefer a ’regional deep cooperation’ model. Novartis can have priority cooperation rights and new indication joint developnt rights for system regulation therapy in the European market, but it is not absolutely exclusive. We retain the possibility of cooperating with other top institutions in specific subfields. Of course, as a deep partner, Novartis will enjoy the most favorable terms in revenue sharing, technological coevolution, and future new therapy expansion."
The eting lasted the entire morning.
Both sides engaged in in-depth, and sotis even intense, discussions on frawork principles, data standards, training courses, revenue models, intellectual property ownership, especially new discoveries derived from core theories. The thorough preparation, rigorous logic, and deep understanding of theory by Huang Jiacai’s team made a deep impression on the Novartis team. They realized this was not a simple business negotiation but more like participating in designing a blueprint for the future dical business model.
The lunch was a simple buffet, but the exchange continued.
Seemingly casually, Huang Jiacai chatted with Collins about the differences in healthcare systems across various European countries and the localization challenges that system regulation therapy might face, demonstrating his profound understanding of the global market.
In the afternoon, the eting resud, involving more specific terms. The lawyers brought by the Novartis team attempted to negotiate more leeway in so legal details, but Ruixing’s legal team could always cite more specific cases or foundational agreent terms to resolve or guide them to solutions more in line with the ’ecosystem’s’ overall interests.
As evening approached, the preliminary frawork of the morandum of understanding for cooperation was finally established. No signature was made, but both sides agreed to draft a detailed list of terms based on this frawork within four weeks.
After seeing off the Novartis team, Huang Jiacai returned to his office, slightly loosening his tie in fatigue, but his eyes remained sharp. An assistant served a cup of tea.
"President Huang, Roche will be arriving the day after tomorrow, Glaxo Smith Kline’s Greater China Regional CEO wants to et next week, and several Silicon Valley biotech investnt funds also wish to visit, inquiring about the possibility of early investnt in Ruixing or cooperative incubation projects," the assistant reported the schedule.
"Arrange according to the plan. Rember the principle: when pharmaceutical companies discuss specific cooperation, they must follow our model; we don’t et with investnt funds, Ruixing has no plans to go public or introduce investnt," Huang Jiacai clearly instructed.
At this mont, the Sanbo Research Institute was indeed imrsed in a bustling and pure scientific environnt.
In the small eting room, Yang Ping, Tang Shun, Lu Xiaolu, Jiang Jitong, Chu Xiaoxiao, and others were conducting the third round of in-depth analysis revolving around the latest data of a patient nad Lina from Heidelberg. The big screen displayed dynamic changes in the tagenomic sequencing of intestinal flora, with abundance curves of various taxa resembling intertwined roller coaster tracks.
User Comments
0 comments from readers